SCHEMBL4414366

SCHEMBL4414366

CC(=O)Nc1ccc(CN2CC3C(CNC(=O)c4ccc(N5CCOCC5)c(F)c4)C3C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 4/20 0.49
SMN1; SMN2 Q16637 5/20 0.48
ALDH1A1 P00352 4/20 0.48
LMNA P02545 4/20 0.48
MAPT P10636 2/20 0.48
NPC1 O15118 5/20 0.46
RAB9A P51151 4/20 0.46
CYP2C9 P11712 1/20 0.46
TP53 P04637 2/20 0.46
MAOA P21397 1/20 0.45
PTGS1 P23219 1/20 0.45
MAOB P27338 1/20 0.45
CALML3 P27482 1/20 0.45
SDHA P31040 1/20 0.45
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 1/20 0.43
F10 P00742 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412120 0.91 USP30 (0.51) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4413697 0.90 USP30 (0.53) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4552123 0.90 USP30 (0.52) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4419281 0.89 USP30 (0.51) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4419241 0.89 USP30 (0.53) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4420887 0.88 USP30 (0.49) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4415909 0.88 USP30 (0.51) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4414369 0.88 L3MBTL1 (0.47) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL2179227 0.87 USP30 (0.49) USP30SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL4421358 0.87 USP30 (0.50) USP30SMN1; SMN2ALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 USP30 4095/4885SMN1; SMN2 4003/4885ALDH1A1 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.